IP

ImmunoPrecise Antibodies (IPA) is an advanced biotherapeutic research and technology group that leverages a multi-platform approach to antibody discovery and development. The company operates as both a high-end Contract Research Organization (CRO) and a drug discovery engine through its subsidiaries, Talem Therapeutics and BioStrand. By integrating artificial intelligence and machine learning via its HYFT technology, IPA aims to accelerate the identification of high-affinity, therapeutic antibodies across various modalities, including bispecifics and ADCs. Their business model combines fee-for-service revenue with long-term value creation through internal pipeline development and strategic partnerships in oncology, infectious diseases, and inflammation.